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Abstract
Despite the advent of antiretroviral therapy, complications of HIV-1 infection with concurrent drug abuse are an emerging
problem. Morphine, often abused by HIV-infected patients, is known to accelerate neuroinflammation associated with HIV-1
infection. Detailed molecular mechanisms of morphine action however, remain poorly understood. Platelet-derived growth
factor (PDGF) has been implicated in a number of pathological conditions, primarily due to its potent mitogenic and
permeability effects. Whether morphine exposure results in enhanced vascular permeability in brain endothelial cells, likely
via induction of PDGF, remains to be established. In the present study, we demonstrated morphine-mediated induction of
PDGF-BB in human brain microvascular endothelial cells, an effect that was abrogated by the opioid receptor antagonist-
naltrexone. Pharmacological blockade (cell signaling) and loss-of-function (Egr-1) approaches demonstrated the role of
mitogen-activated protein kinases (MAPKs), PI3K/Akt and the downstream transcription factor Egr-1 respectively, in
morphine-mediated induction of PDGF-BB. Functional significance of increased PDGF-BB manifested as increased breach of
the endothelial barrier as evidenced by decreased expression of the tight junction protein ZO-1 in an in vitro model system.
Understanding the regulation of PDGF expression may provide insights into the development of potential therapeutic
targets for intervention of morphine-mediated neuroinflammation.
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Introduction
Opiates abuse has been implicated as a contributing risk factor
for increased neuroinflammation associated with various neuro-
degenerative disorders. Increasing often used for pain manage-
ment has been shown to not only accelerate HIV-1 replication
while causing immunosuppression, but can also exacerbate
neuropathogenesis associated with AIDS [1,2,3,4]. In fact,
evidence of more severe pathology has been observed at autopsy
[5] in patients with cancer metastasis, kidney and lung disease and
in brains of HIV-1 infected individuals that were opiate users.
Despite the recognized impact of the abuse of morphine on the
disease pathology, the underlying mechanisms involved in this
process remain elusive.
In our previous study we have demonstrated increased
expression of PDGF in the brains of macaques with SIV-
encephalitis [6]. Specifically, PDGF-BB was present in perivascu-
lar macrophages lining the small blood vessels in the brain [6]. In
this previous study, however, the contribution of endothelial cells
as a source of PDGF-BB was not investigated. The present study
was undertaken to examine whether morphine exposure of human
brain microvascular endothelial cells (HBMECs) resulted in
increased PDGF-BB expression, and if so, did this overexpresssion
lead to disruption of endothelial cell integrity.
PDGF is a known mitogen & chemoattractant for a number of
cell types both in vitro and in vivo [7,8] and can activate
transcription of a number of otherwise quiescent genes, several
of which are known to encode potent cytokines and proto-
oncogenes [9]. To date four known PDGF ligands (A–D) have
been identified that can exert their effect via specific cell
membrane tyrosine kinase receptors designated a & b [10,11].
PDGF has been implicated in pathologies of the lung, heart, brain
and various tumors [6,12]. Its role in drug abuse-induced CNS
complication however, remains elusive. Recent intriguing findings
by Su et al have implicated PDGF released from astrocytes as a
critical factor in the disruption of cerebrovascular permeability
leading to increased risk for stroke [12].
Blood-brain barrier (BBB) is critical for the maintenance of
CNS homeostasis and for the regulation of the neuronal
microenvironment. While neuroinflammation is one of the
hallmark features of morphine-induced CNS aberration [1],
information on factors mediating the BBB breach is scanty. Based
on its role as a vascular permeant, we hypothesized that PDGF-BB
was critical for inducing morphine-mediated disruption of the
endothelial barrier.
The present study was aimed at exploring the signaling
mechanisms by which morphine mediated induction of PDGF-B
chain in HBMECs and its functional implications for increased
neuroinflammation. Specifically, this study aims to focus on the
mitogen-activated protein kinase mediators such as Erk, JNK,p38
and PI3K/Akt pathways that have previously been shown to be
regulated by morphine [13,14]. Understanding the regulation of
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development of potential therapeutic targets aimed at intervening
influx of inflammatory cells into the CNS.
Materials and Methods
Materials
Morphine and the opioid receptor antagonist naltrexone were
purchased from Sigma (St. Louis, MO). The specific Phosphati-
dinylinositol-39 (PI3K) inhibitor LY294002, MEK inhibitor
U0126, JNK inhibitor SP600125 and P38 inhibitor SB203580
were obtained from Calbiochem (San Diego, CA). Chromatin
immunoprecipitation (ChIP) assay kit was purchased from Upstate
(Billerica, MA). Dominant negative and constitutively active
constructs of Egr-1 were provided by Dr. Young Han Lee
(Konkuk University, Korea).
Cell culture and treatment
Primary HBMECs obtained from Dr. Monique Stins (Johns
Hopkins University) were cultured in RPMI 1640 medium
containing 10% heat-inactivated fetal bovine serum, 10% Nu-
Serum, 2 mM glutamine, 1 mM pyruvate, penicillin (100 units/
ml), streptomycin (100 mg/ml), essential amino acids, and
vitamins. Purified HBMECs were positive for endothelial makers
DiI-AcLDL (left panel), ZO-1 (middle panel) and b-catenin (right
panel) and were found to be .99% pure after exclusion of staining
for non-endothelial cell type markers (GFAP, smooth muscle actin,
cytokeratin and macrophage antigens) as described previously
[15]. For pharmacological inhibition studies, cells were pre-treated
for 1 h with naltrexone (10 mM), Phosphatidinylinositol-39 (PI3K)
inhibitor LY294002 (10 mM), MEK inhibitor U0126 (20 mM),
JNK inhibitor SP600125 (20 mM), and P38 inhibitor SB203580
(20 mM), prior to morphine treatment. The concentrations of
morphine and these inhibitors were based on the dose-curve study
previously reported by us [16,17,18]. All experiments were
conducted under serum-free conditions because serum is known
to induce PDGF [19].
Real-Time PCR
Total RNA was extracted using Trizol reagent according to the
manufacturer’s protocol (Invitrogen Life Technologies, CA). 1 mg
of RNA was used for cDNA production according to manufac-
turer’s instructions (Thermo Scientific, MA). Human PDGF-B
primer was obtained from SA Biosciences (Frederick, MD).
Quantitative Analyses of mRNA were conducted using ABI
7500 Fast Real-Time PCR system (Applied Biosystems, CA). Data
were normalized using Ct values for b-actin in each sample. To
calculate relative amounts mRNA, the average Ct values were
subtracted from b-actin values for each target gene to provide
changes in Ct value. Fold Change in expression was calculated as
log2 relative units.
Western Blotting
Treated cells were washed with PBS buffer followed by lysis
using the Mammalian Cell Lysis kit (Sigma, St. Louis, MO). Cell
lysates were subjected to protein separation using 10% SDS-
PAGE electrophoresis (equal amounts of the corresponding
proteins, about 25 mg protein per well) followed by transferring
of protein onto polyvinylidene difluoride membrane. The blots
were blocked with 5% non-fat dry milk in PBS. Western blots were
then probed with antibodies recognizing Egr-1 (Santa Cruz, CA,
1:500), PDGF-BB (Santa Cruz, CA 1: 1000), ZO-1 (Invitrogen,
CA, 1:200), b-actin (Santa Cruz, CA, 1:5000) and phosphorylated
forms of Erk1/2, JNK, p38 and Akt (Cell Signaling, Danvers, MA,
1:200). Signals were detected by chemiluminescence (Pierce,
Rockford, IL).
Immunocytochemistry and Imaging
Immunocytochemical analysis of Egr-1 and PDGF-BB expres-
sion were performed in morphine-treated and untreated HBMECs
grown on round glass coverslips. Following morphine treatment,
cells were treated with 4% paraformaldehyde for 15 min at room
temperature and permeabilized with PBS containing 0.3% Triton
X-100 for 30 min at room temperature. After blocking with PBS
containing 10% normal goat serum, cells were incubated at 4uC
overnight with either anti-Egr-1 or anti-PDGF-BB (both at 1:200
dilution) rabbit polyclonal antibodies (Santa Cruz Biotechnology).
After washing, cells were incubated with the secondary goat anti-
rabbit AlexaFluor 488 and 594-conjugated antibody (1:500) for
PDGF-BB and Egr-1 respectively. For negative controls, cells were
treated as described above without the primary antibody. Cells
were mounted with Prolong Gold containing 49,6 9-diamidino-2-
phenylindole to stain nuclei (Molecular Probe, Eugene,OR).
Immunostaining was observed using a microscope (ZEISS).
Transfection with plasmid constructs
HBMECs were transfected with plasmid vectors containing
either wild type (WT) or dominant negative (DN) forms of Egr-1 as
described previously [20]. Knock-down efficiencies were deter-
mined by Western Blotting.
Chromatin immunoprecipitation (ChIP) Assay
ChIP assay was performed according to the manufacturer’s
instructions. After treatment the cells with morphine, 18.5% fresh
formaldehyde was added directly into the medium at a final
concentration of 1% formaldehyde and incubated for 10 min at
room temperature, followed by quenching with 106glycine. The
cells were then scraped using 2 ml pre-chilled PBS containing
16protease inhibitor cocktail. The cell pellet was harvested by
spinning at 8006ga t4 uC followed by adding lysis buffer (provided
in the kit) to harvest nuclei. DNA was sheared by sonication. 50 ml
of the sheared cross-linked chromatin was then mixed with 20 ml
of protein A magnetic beads and 5 mg of the corresponding
antibody diluted in 450 ml dilution buffer followed by incubation
overnight at 4uC. The magnetic beads binding antibody/
chromatin complex was then washed with 0.5 ml each of a series
of cold wash buffers in the order of low salt buffer, high salt buffer,
LiCl buffer and finally with Tris-EDTA buffer. The cross-linked
protein/DNA complexes were reversed to free DNA by
incubation at 62uC for 2 h, and purified using DNA purification
spin columns following the manufacturer’s instructions. Finally the
purified DNA was amplified via PCR to identify promoter region
containing Egr-1 binding site ‘‘GCG GGG GCG’’. The sequence
of the primers used to identify the PDGF-B promoter bound to
Egr-1 were as follows: sense, 59-GCAGAGGCCTGAGCGCCT-
GATC-39, anti–sense, 59-GCAGCGATTCATGCCGACTCCG-
39.
Cell Permeability
Primary HBMECs at passage 18 were seeded (4610
4cells/well)
onto 6.5-mm polyester Transwell inserts (0.4-mm pore size) and
grown for 5 days to achieve confluence. HBMEC monolayers
were generated and treated with 10
27 M of morphine, in the
presence or absence of naltrexone, neutralizing PDGF-BB
antibody or isotype antibody for the times indicated. To detect
changes in monolayer permeability, following incubation for 24 h,
FITC Dextran-4 (1 mg/ml; Sigma) was added to the upper
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2 h. Aliquots (100 ml) were then collected from the lower chamber
for fluorescent measurement using 480 and 530 nm for excitation
and emission, respectively (Biotek Synergy MX multimode
microplate reader instrument). The fluorescence intensity of each
well was subtracted by that of medium alone without Transwell
insert incubation. Permeability changes were expressed as
percentage of FITC-dextran transported across the BBB into the
lower chamber compared to untreated control cultures.
Statistical Analysis
Statistical analysis was performed using one-way analysis of
variance with a post hoc student t test. Results were judged
statistically significant if p,0.05 by analysis of variance.
Results
Morphine mediated up-regulation of PDGF-B expression
in HBMECs
To assess the dose-curve of morphine effect, serum-starved
HBMECs were first treated with varying concentrations of
morphine (10
25,1 0
26 and 10
27 M) for 12 h and assessed for
expression of PDGF-BB by western blotting. As shown in Fig. 1A,
maximal induction of PDGF-BB was at a morphine concentration
of 10
27 M. The rationale for using this concentration range for
morphine was based on our previously published report [16]. This
concentration was thus used for all further experiments. The next
step was to determine the time course of morphine-mediated
induction of PDGF-BB. As shown in Fig. 1B, exposure of serum-
starved HBMECs to morphine for varying times (5–30 min; 1–
24 h) resulted in time-dependent induction of PDGF-BB
with a maximal response at 12 h, followed by a gradual decline
thereafter. To examine whether morphine-mediated induction of
PDGF-BB involved the opioid receptor cells were also pretreated
the receptor antagonist, naltrexone (1 mM) followed by treatment
with morphine at 12 h. As shown in Fig. 1C, naltrexone abrogated
morphine-mediated up-regulation of PDGF-BB. Confirmation of
these findings by immunostaining also revealed increased
expression of PDGF-BB in morphine-exposed HBMECs 12 h
post-treatment (Fig. 1D). Consistent with the protein levels,
morphine exposure also increased mRNA for PDGF-B chain as
determined by Real Time-PCR with a maximal up-regulation (2.9
fold) at 6 h (Fig. 1E), preceding the peak protein expression at
12 h. Cumulatively, these data clearly demonstrate that exposure
of HBMECs to morphine resulted in opioid receptor -mediated
induction of PDGF-B chain RNA and PDGF-BB protein.
Morphine-mediated induction of PDGF-BB via the opioid
receptor involves activation of Erk1/2, JNK and p38 MAPK
but not PI3K/Akt signaling pathways
Having determined morphine-mediated induced expression of
PDGF-B chain in HBMECs, we next sought to elucidate the
signaling pathways involved in this process. Since morphine can
activate mitogen-activated protein kinase (MAPK) pathways [21],
we examined the involvement of Erk1/2, JNK and p38 kinases in
morphine-induced expression of PDGF-BB. Treatment of
HBMECs with morphine resulted in a time-dependent increase
in phosphorylation of Erk1/2, JNK, p38 and Akt (Fig. 2A).
Next, we wanted to know whether morphine-mediated
induction of PDGF-BB involved activation of these signaling
pathways. HBMECs were pre-treated with inhibitors specific for
the respective signaling pathways prior to stimulation with
morphine and assessed for expression of PDGF-BB. As shown in
Fig. 2B–C, pre-treatment of cells with inhibitors specific for MEK
(U0126, 20 mM), JNK (SP600125, 20 mM), p38 (SB203580,
20 mM) but not PI3K (LY294002, 10 mM) resulted in amelioration
of morphine-mediated induction of PDGF-BB. These findings
underpin the role of Erk1/2, JNK and p38 MAPKs but not PI3K/
Akt cascade in morphine-mediated induction of PDGF-BB in
HBMECs.
Transcription factor Egr-1 is activated in HBMECs
exposed to morphine
Having determined the involvement of Erk1/2, JNK and p38
MAPK in morphine-mediated induction of PDGF-BB expression,
we next wanted to assess the downstream signaling mediators
involved in this process. Based on the published reports
demonstrating the presence of binding sequences for the
transcription factor, early growth response (Egr)-1 on the PDGF-
B promoter [22], we rationalized that morphine-mediated
induction of PDGF-BB could likely involve the downstream
effector Egr-1. Exposure of HBMECs to morphine resulted in a
time-dependent increase in Egr-1 expression (Fig. 3A), with a peak
expression at 1 h post-treatment and a decline thereafter. These
findings were also validated by Egr-1 immunostaining demon-
strating increased Egr-1 expression in morphine-treated HBMECs
at 1 h post-treatment (Fig. 3B).
Next logical step was to examine whether there existed a link
that could tie morphine-mediated activation of Erk1/2, JNK, p38
MAPKs and PI3K-Akt pathways with Egr-1 and, if so, the
involvement of opioid receptor in this process. HBMECs were pre-
treated with naltrexone, and MEK, JNK, p38 or PI3K inhibitors
followed by treatment with morphine and assessed for activation of
Egr-1. As shown in Fig. 3C–D, exposure of HBMECs to opioid
receptor antagonist and either MEK, JNK or p38 inhibitors
resulted in abrogation of morphine-mediated activation of Egr-1.
Intriguingly, pre-treatment of cells with the PI3K inhibitor had no
effect on morphine-mediated activation of Egr-1. These findings
thus linked morphine-mediated activation of Erk1/2, JNK and
p38 signaling pathways to downstream activation of Egr-1 with an
involvement of opioid receptor in this process.
Involvement of Egr-1 in morphine-induced expression of
PDGF-BB in HBMECs
Next we wanted to confirm the role of Egr-1 in morphine-
mediated induction of PDGF-BB. HBMECs were transfected with
either the WT or DN construct of Egr-1, followed by treatment
with morphine and assessed for expression of PDGF-BB by WB.
As shown in Fig. 4A, morphine-mediated induction of PDGF-BB
was attenuated by the DN-Egr-1, but not the WT-Egr-1 construct
further validating the pharmacological approach described above.
To confirm the binding of Egr-1 with PDGF-B promoter in its
natural chromatin context, we performed chromatin immunopre-
cipitation assay to reveal active sites on the PDGF-B promoter that
are accessible to Egr-1. HBMECs were treated with morphine for
1 h followed by analysis using a ChIP kit. These experiments
revealed increased binding of Egr-1 to the PDGF-B promoter in
HBMECs exposed to morphine (Fig. 4B–C). Collectively, these
findings emphasize the role of Egr-1 in morphine-mediated
induction of PDGF-BB.
Morphine-mediated disruption of ZO-1 expression
involves PDGF-BB
The next step was to identify the role of up-regulated PDGF-BB
in HBMECs. Since PDGF-BB is a known vascular permeant, we
rationalized that morphine-mediated upregulation of PDGF-BB
Morphine Induced PDGF-BB Expression
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downregulation of the tight junction protein ZO-1. HBMECs
were exposed to morphine and assessed for the expression of ZO-1
by Western blot. As shown in Fig. 5A, treatment of HBMECs with
morphine resulted in a time-dependent decrease in the expression
of ZO-1 and, this effect was significantly ameliorated in cells pre-
treated with either naltrexone or PDGF-BB neutralizing antibody
(Fig. 5B). These findings thus underscored the role of PDGF-BB in
morphine/opioid receptor axis-mediated down regulation of
ZO-1.
Morphine-mediated induction of PDGF-BB increases BBB
permeability
Functional relevance of PDGF-BB-mediated down-regulation of
ZO-1 was further confirmed using in vitro permeability assays. As
shown in Fig. 6, exposure of HBMECs monolayer to morphine
increased monolayer permeability by almost 30%. Intriguingly,
pre-treatment of HBMECs with either naltrexone or PDGF-BB
neutralizing antibody significantly ameliorated morphine-induced
leakiness of the BBB, thereby underpinning the role of opioid
receptor and PDGF-BB in this process.
Discussion
Mounting evidence indicated that drug abuse speeds up the
progression to AIDS in HIV-infected individuals and exacerbates
neurological complications associated with the disease [2,16,23].
Morphine increases the activation of astrocytes and macrophages/
microglia in the brain through regulation of diverse pro-
inflammatory cytokines and chemokines [24,25]. Morphine has
also been shown to alter BBB function by regulating the expression
Figure 1. Morphine-mediated induction of PDGF-B chain expression in human brain microvascular endothelial cells. (A) Dose-
dependent induction of PDGF-BB protein by morphine (10
25,1 0
26 and 10
27 M) in human brain microvascular endothelial cells (HBMECs). (B) Time-
dependent induction of PDGF-BB protein by morphine (10
27 M) in HBMECs. (C) Opioid receptor antagonist naltrexone (1 mM) abrogates morphine-
mediated induction of PDGF-BB. (D) Representative picture of PDGF-B chain staining in HBMECs treated with morphine for 12 hrs. Scale bar=5 mm.
(E) Induction of PDGF-B mRNA in HBMECs exposed to morphine after 6 hrs. All the data are presented as mean6SD of three individual experiments.
*p,0.05, ***p,0.001 vs control group; ###p,0.001 vs morphine group.
doi:10.1371/journal.pone.0021707.g001
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PDGF-BB in HBMECs. (A) Time-dependent activation of Erk1/2, JNK, p38 and Akt by morphine as evidenced by western blot analysis. Pretreatment
of HBMECs with the inhibitors specific for Erk1/2-U0126 20 mM (B), JNK-SP600125 20 mM (B) and p38-SB203580 20 mM (C) but not Akt-LY294002
10 mM) (B) pathways abrogates morphine-mediated induction of PDGF-BB. All the data are presented as mean6SD of three individual experiments.
***p,0.001 vs control group; ###p,0.001 vs morphine group.
doi:10.1371/journal.pone.0021707.g002
Figure 3. Egr-1 expression is up-regulated in HBMECs exposed to morphine. (A) Time-dependent activation of Egr-1 protein expression by
morphine in HBMECs. (B) Representative image of Egr-1 staining in HBMECs treated with morphine. Scale bar=5 mm. Pretreatment of HBMECs with
the inhibitors specific for Erk1/2-U0126 20 mM,JNK-SP600125 20 mM( C) and p38-SB203580 20 mM( D) but not Akt-LY294002 10 mM( C) pathways
abrogates morphine-mediated induction of Egr-1. All the data are presented as mean6SD of three individual experiments. ***p,0.001 vs control
group; #p,0.05, ###p,0.001 vs morphine group.
doi:10.1371/journal.pone.0021707.g003
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membrane protein (P-glycoprotein) [1,26]. However, very few
studies have actually explored direct effects of morphine on the
expression of a cerebrovascular permeant PDGF-BB. Our study
demonstrates for the first time that morphine-mediated disruption
of BBB involves up-regulation PDGF-BB in HBMECs.
In the present study we demonstrated that exposure of
HBMECs to morphine resulted in induction of PDGF expression
at both the transcriptional and translational levels through the
binding of morphine to the opioid receptor. Further dissection of
the signaling pathways involved in morphine-mediated induction
of PDGF-BB using pharmacological and genetic approaches
revealed activation of Erk, JNK, p38 MAPKs and also PI3K/Akt
pathways, a finding that is consistent previous reports on the effect
of morphine in neurons [27]. Morphine-mediated induction of
PDGF-BB expression however, involved Erk, JNK and p38
MAPKs, but not PI3K/Akt pathway. These findings are in
agreement with previous reports demonstrating morphine-medi-
ated activation of the MAPK and PI3K-Akt pathways, similar to
the effects of vascular endothelial growth factor (VEGF) on mouse
retinal endothelial cells [13,14]. It is likely that morphine-induced
activation of MAPKs and PI3K/Akt pathways could be due to the
co-activation of VEGFR2 and PDGF-bR [28]. In our studies
morphine increased endothelial permeability in HBMECs, which
is in keeping with a pervious reciprocal finding that mu opioid
receptor-specific antagonist methylnaltrexone inhibited morphine-
induced vascular permeability [29]. It must be pointed out that in
another unrelated paradoxical study, morphine has been suggested
to inhibit expression of another vascular permant such as VEGF
that is induced by hypoxia both in endothelial cells as well as
cardiac myocytes [30,31]. One possible explanation for this
disparity in regulation of VEGF versus PDGF, could be attributed
to the fact that since both these factors belong to a family of related
growth factors, upregulation of PDGF could be a compensatory
mechanism for reduced VEGF expression mediated by morphine.
The transcription factor, Egr-1, has been found to be a major
regulatory transcription factor for PDGF-BB in several types of
cells [32,33]. In this study, our findings demonstrated a time-
dependent up-regulation of Egr-1 protein in HBMECs (Fig. 3A),
and the CHIP assay results confirmed the regulation of Egr-1 in
the transcriptional activation of PDGF-BB (Fig. 4C). Further
dissection of Egr-1 regulation using both the pharmacological and
genetic approaches revealed the activation of Erk, JNK and p38
MAPKs pathways upstream of Egr-1 (Fig. 2). In agreement with
our findings, activation of Erk, JNK Egr-1 pathway has also been
shown to play a role in FGF-2 treated astrocytes [34].
Figure 4. Involvement of Egr-1 in morphine-mediated induction of PDGF-BB in HBMECs. (A) Whole cell lysates of HBMECs transfected
with either the wild type (WT) or dominant negative (DN) construct of Egr-1 were subject to western blot analysis using antibodies specific for PDGF-
BB. Transfection of cells with the DN-Egr-1, but not the WT-Egr-1 inhibited morphine-mediated induction of PDGF-BB expression. (B) Schematic
illustration of Egr-1 binding consensus sequence on the PDGF-B promoter region. (C) ChIP assay demonstrating morphine-mediated binding of Egr-1
to the PDGF-B promoter. All the data are presented as mean6SD of three individual experiments. ***p,0.001 vs control group.
doi:10.1371/journal.pone.0021707.g004
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also demonstrated increased Egr-1 binding to the PDGF-B promoter
in morphine-treated HBMECs (Fig. 4), thus confirming the role of
Egr-1 in PDGF-BB expression. Further support of Egr-1 involvement
in morphine-mediated PDGF-BB induction was also demonstrated
using genetic approaches. Our findings are in agreement with the
report by Khachiganet al.demonstratinginteraction ofEgr-1withthe
PDGF-B promoter in arterial endothelial cells [22].
Functional implication of morphine-mediated induction of
PDGF-BB was also assessed in an in vitro model of BBB. Exposure
of HBMECs to morphine resulted in down-regulation of the tight
junction protein ZO-1 with the involvement of both MOR and
PDGF-BB as evidenced in cells treated with the natlrexone and
PDGF-B neutralizing antibody, respectively. These findings are in
agreement with the recent studies implicating the role of PDGF
family members as mediators of BBB damage [12,20].
Figure 5. PDGF-BB induces down regulation of ZO-1 in HBMECs. (A) Time-dependent reduction of ZO-1 protein expression by morphine in
HBMECs. (B) Treatment of cells with either the opioid receptor antagonist (naltrexone) or PDGF-BB neutralizing antibody results in inhibition of ZO-1
expression. All the data are presented as mean6SD of at least three individual experiments. ***p,0.001 vs control group; ###p,0.001 vs
morphine-treated group.
doi:10.1371/journal.pone.0021707.g005
Figure 6. Effect of morphine on BBB permeability in vitro. Morphine-mediated increase in BBB permeability was ameliorated in HBMECs
pretreated with either naltrexone or PDGF-BB neutralizing antibody. All the data are presented as mean6SD of four individual experiments. *p,0.05
vs control group; #p,0.05 vs morphine-treated group.
doi:10.1371/journal.pone.0021707.g006
Morphine Induced PDGF-BB Expression
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21707In summary, our findings demonstrate a detailed molecular
pathway of morphine-mediated induction of PDGF-BB in
HBMECs, involving engagement of opioid receptor and activation
of Erk, JNK and p38 MAPK pathways and the downstream
transcription factor Egr-1 leading to increased expression of
PDGF-BB, culminating ultimately into BBB damage. These
findings have implications for HIV-1-infected heroin abusers that
are known to have increased risk of neuroinflammation.
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